<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Small intestinal bacterial overgrowth: Management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Small intestinal bacterial overgrowth: Management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Small intestinal bacterial overgrowth: Management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nicholas J Talley, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">J Thomas Lamont, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Shilpa Grover, MD, MPH, AGAF</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 18, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Small intestinal bacterial overgrowth (SIBO) is a condition in which the small bowel is colonized by excessive aerobic and anaerobic microbes. The majority of patients with SIBO present with bloating, flatulence, abdominal discomfort, or diarrhea or constipation in the case of intestinal methanogen overgrowth (IMO). This topic will review the management of SIBO. The etiology, pathogenesis, clinical manifestations, and diagnosis of SIBO are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H922218135"><span class="h1">INITIAL APPROACH</span><span class="headingEndMark"> — </span>The mainstay of therapy for SIBO are antibiotics to reduce (rather than eradicate) small intestinal bacteria. In addition, some patients require treatment of underlying nutritional deficiencies and associated ileitis/colitis.</p><p class="headingAnchor" id="H4"><span class="h2">Antibiotic therapy</span><span class="headingEndMark"> — </span>Antibiotic therapy is typically begun after confirming SIBO by breath test. The selection of antimicrobial regimens is based on the pattern of bacterial overgrowth, the prevalence of risk factors for drug-resistance (recent or repeated prior exposure), relevant antibiotic allergies, and cost [<a href="#rid1">1</a>]. It is unnecessary to repeat breath testing if symptoms resolve with treatment. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Carbohydrate breath test'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Small intestinal bacterial overgrowth </strong>– In patients with small intestinal bacterial overgrowth, we use <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> (1650 mg per day for 14 days). Rifaximin is non-absorbable rifamycin derivative. It is well tolerated and has been demonstrated to be effective in the treatment of SIBO [<a href="#rid2">2-8</a>]. However, the high cost of rifaximin has limited its use. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intestinal methanogen overgrowth (IMO) </strong>–<strong> </strong>In patients with IMO, we use a combination of <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a> 500 mg twice daily and <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> 550 mg 3 times daily for 14 days [<a href="#rid9">9,10</a>]. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Carbohydrate breath test'</a>.)</p><p></p><p>Alternative antibiotics for treatment of SIBO include <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9710" href="/z/d/drug information/9710.html" rel="external">norfloxacin</a>, <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">metronidazole</a>, <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">tetracycline</a>, or amoxicillin-clavulanic acid [<a href="#rid10">10</a>]. Alternative antibiotic regimens for the treatment of SIBO are listed in the table  (<a class="graphic graphic_table graphicRef107297" href="/z/d/graphic/107297.html" rel="external">table 1</a>).<strong> </strong>There are few randomized trials of antibiotics to treat bacterial overgrowth and the evidence for use of specific antibiotics is largely from observational studies [<a href="#rid2">2-8</a>]. Studies suggest that clinical response rates may be higher with <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> than other antibiotics. In a randomized controlled trial in which 142 patients with SIBO were randomized to seven days of rifaximin (1200 mg per day) or metronidazole (750 mg per day), glucose breath test normalization rates at one month were significantly higher in patients treated with rifaximin compared with metronidazole (63 versus 44 percent). Treatment of SIBO with high hydrogen sulfide is still under study. (See <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H153040933"><span class="h2">Correction of micronutrient deficiency</span><span class="headingEndMark"> — </span>Deficiencies of vitamin B12, fat-soluble vitamins, iron, thiamine, and niacin can be associated with severe SIBO and should be corrected when present. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Laboratory findings'</a> and  <a class="medical medical_review" href="/z/d/html/7154.html" rel="external">"Treatment of vitamin B12 and folate deficiencies", section on 'Vitamin B12'</a> and  <a class="medical medical_review" href="/z/d/html/2022.html" rel="external">"Vitamin D deficiency in adults: Definition, clinical manifestations, and treatment", section on 'Vitamin D replacement'</a> and  <a class="medical medical_review" href="/z/d/html/5367.html" rel="external">"Overview of water-soluble vitamins"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Treatment of associated ileocolitis</span><span class="headingEndMark"> — </span>SIBO-associated ileitis or colitis is usually mild and resolves with treatment of SIBO. However, severe cases require treatment that is the same as for patients with inflammatory bowel disease [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/z/d/html/4069.html" rel="external">"Overview of the medical management of mild (low risk) Crohn disease in adults"</a>.)</p><p class="headingAnchor" id="H2284992923"><span class="h1">TREATMENT RESPONSE AND RECURRENCE</span><span class="headingEndMark"> — </span>Approximately 40 percent of patients with small intestinal bacterial overgrowth (SIBO) have persistent symptoms after initial antibiotic treatment [<a href="#rid12">12</a>]. Recurrent SIBO is also frequent after antibiotic treatment. In a study involving 80 patients with SIBO, recurrence rates three, six, and nine months after successful treatment with <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> were 13, 28, and 44 percent, respectively [<a href="#rid12">12</a>]. Recurrence was more likely in older adults, those with a history of an appendectomy, and with chronic proton pump inhibitor (PPI) use. </p><p class="headingAnchor" id="H3896841013"><span class="h1">INADEQUATE RESPONSE TO INITIAL THERAPY OR RECURRENCE</span></p><p class="headingAnchor" id="H4128173248"><span class="h2">Evaluation</span><span class="headingEndMark"> — </span>We empirically treat patients with a second course of antibiotics if they have a partial improvement in symptoms or early recurrence (&lt;3 months). For patients with recurrent symptoms ≥3 months after initial antibiotic treatment, a repeat breath test can confirm recurrence of SIBO. Patients with no improvement in symptoms after two courses of antibiotic therapy or progressive symptoms should be evaluated for alternative diagnoses. (See  <a class="medical medical_review" href="/z/d/html/6862.html" rel="external">"Evaluation of the adult with abdominal pain"</a> and  <a class="medical medical_review" href="/z/d/html/2591.html" rel="external">"Approach to the adult with chronic diarrhea in resource-abundant settings"</a>.)</p><p class="headingAnchor" id="H4229245687"><span class="h2">Subsequent antibiotic regimen</span><span class="headingEndMark"> — </span>In patients with partial response to recurrent SIBO, the choice of antibiotic therapy should be guided by the patient's initial treatment regimen. Antibiotics included in the initial regimen should generally be avoided. However, patients with an inadequate initial response or recurrent SIBO after treatment with <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> can be retreated with a course of rifaximin or an alternative antibiotic [<a href="#rid13">13</a>]. Alternative antibiotic regimens are also summarized in the following table  (<a class="graphic graphic_table graphicRef107297" href="/z/d/graphic/107297.html" rel="external">table 1</a>). Compliance with antibiotic therapy should be reinforced.</p><p class="headingAnchor" id="H3161411024"><span class="h2">Elemental diet</span><span class="headingEndMark"> — </span>We reserve the use of an elemental diet to patients who cannot tolerate antibiotics or have failed to respond to antibiotic therapy for SIBO. Limited observational data suggest that an elemental diet can induce remission of symptoms in patients with SIBO. However, elemental diets are expensive and compliance is limited by palatability. In a retrospective study, 124 patients with methane- or hydrogen-predominant SIBO were treated exclusively with elemental diet for at least two weeks [<a href="#rid14">14</a>]. Patients continued the diet for a total of three weeks if the breath test did not normalize by week two. At two weeks, 74 of 93 patients (80 percent) had a normal breath test. Five of 19 subjects who were treated with an elemental diet for an additional week had a normal breath test by day 22 for a cumulative response of 85 percent. Patients who normalized their breath test had a significant improvement in symptoms as compared with those with persistently abnormal breath tests (66 versus 12 percent). Fourteen patients discontinued the elemental diet and were excluded from the analysis.</p><p class="headingAnchor" id="H1830639388"><span class="h1">PREVENTION OF RECURRENCE</span></p><p class="headingAnchor" id="H393248297"><span class="h2">Treat the underlying etiology in all patients</span><span class="headingEndMark"> — </span>All patients should receive therapy directed against the underlying etiology of SIBO  (<a class="graphic graphic_table graphicRef81285" href="/z/d/graphic/81285.html" rel="external">table 2</a>). As examples, medications that can decrease intestinal motility (eg, opioids, benzodiazepines) or cause achlorhydria should be avoided when possible. Prokinetics are a useful adjunct in patients with SIBO due to an underlying dysmotility. In the case of iatrogenic surgical causes of SIBO and for fistulas between the proximal and distal intestine, surgery may be necessary in patients who fail to respond to antibiotics and have significant weight loss and diarrhea. Patients with dilated segments of bowel with poor motility may benefit from intestinal tapering procedures. (See  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Evaluation to determine the etiology'</a>.) </p><p class="headingAnchor" id="H1806966980"><span class="h2">Antibiotic prophylaxis in selected patients</span><span class="headingEndMark"> — </span>Antibiotic prophylaxis for SIBO should be reserved for patients with ≥4 distinct and well-documented episodes within one year and risk factors for recurrent SIBO (eg, short bowel syndrome, jejunal diverticulosis). In such patients we administer antibiotics on a periodic basis (5 to 10 days out of every month or every other week). Antibiotics are changed to prevent the development of resistance to a specific drug. The frequency with which antibiotics are rotated varies from monthly to every six months. </p><p class="headingAnchor" id="H120816420"><span class="h2">Interventions with unclear role</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Low fermentation eating or a</strong> <strong>low fermentable oligo-, di-, and monosaccharides and polyols (FODMAP) diet</strong> – FODMAPs are short-chain carbohydrates that are poorly absorbed and are osmotically active in the intestinal lumen where they are rapidly fermented by small intestinal bacteria. A diet low in FODMAPs improves bloating and gas in patients with irritable bowel syndrome, however, evidence to support a low FODMAP diet in the prevention or management of patients with SIBO are lacking. Other low fermentation diets are less restrictive and can be used more long term. (See  <a class="medical medical_review" href="/z/d/html/5375.html" rel="external">"Obesity in adults: Dietary therapy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Probiotics – </strong>There are limited data to support probiotics in the treatment of SIBO [<a href="#rid11">11,15-18</a>]. In a 2017 meta-analysis that included 18 studies there was no significant difference in the incidence of SIBO in patients on probiotics as compared with the control group [<a href="#rid18">18</a>]. Patients with SIBO who were treated with probiotics had higher rates of gut decontamination and decrease in breath hydrogen concentration and abdominal pain but there was no significant improvement in diarrhea.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Statins</strong> – Statins have been shown to inhibit growth and production of methane in several Methanobrevibacter isolates [<a href="#rid19">19</a>]. However, studies in patients with intestinal methanogen overgrowth are lacking.</p><p></p><p class="headingAnchor" id="H2122101777"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/119548.html" rel="external">"Society guideline links: Small intestinal bacterial overgrowth"</a>.)</p><p class="headingAnchor" id="H6"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical significance</strong> – Small intestinal bacterial overgrowth (SIBO) is a condition in which the small bowel is colonized by excessive aerobic and anaerobic microbes. The majority of patients with SIBO present with bloating, flatulence, abdominal discomfort, or watery diarrhea. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial management</strong> – We suggest antibiotic treatment for SIBO with <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">rifaximin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In patients with intestinal methanogen overgrowth, we use a combination of <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">neomycin</a> and rifaximin  (<a class="graphic graphic_table graphicRef107297" href="/z/d/graphic/107297.html" rel="external">table 1</a>). Adequate antimicrobial coverage can also be achieved with other antibiotic combinations. Deficiencies of vitamin B12, fat-soluble vitamins, iron, thiamine, and niacin are usually associated with severe SIBO and require supplementation when present. (See <a class="local">'Antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent or recurrent</strong> <strong>symptoms  </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Approximately 40 percent of patients with SIBO have persistent symptoms after initial antibiotic treatment and 40 percent have recurrent SIBO within nine months of antibiotic treatment. (See <a class="local">'Treatment response and recurrence'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We empirically treat patients with a second course of antibiotics if they have a partial improvement in symptoms or early recurrence (&lt;3 months). For patients with recurrent symptoms ≥3 months after initial antibiotic treatment, we perform a repeat carbohydrate breath test to diagnose SIBO. (See <a class="local">'Inadequate response to initial therapy or recurrence'</a> above and <a class="local">'Evaluation'</a> above and  <a class="medical medical_review" href="/z/d/html/4776.html" rel="external">"Small intestinal bacterial overgrowth: Clinical manifestations and diagnosis", section on 'Carbohydrate breath test'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with persistent symptoms after two courses of antibiotic therapy or progressive symptoms should be evaluated for alternative diagnoses. We reserve the use of an elemental diet to patients who cannot tolerate antibiotics or have failed to respond to antibiotic therapy for SIBO. (See <a class="local">'Evaluation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of the underlying etiology and recurrence prevention</strong> – All patients should receive therapy directed against the underlying etiology of SIBO  (<a class="graphic graphic_table graphicRef81285" href="/z/d/graphic/81285.html" rel="external">table 2</a>). We reserve antibiotic prophylaxis for SIBO for selected patients with multiple recurrences of SIBO and risk factors for recurrence (eg, short bowel syndrome, jejunal diverticulosis). (See <a class="local">'Prevention of recurrence'</a> above.)</p><p></p><p class="headingAnchor" id="H22047180"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jon Vanderhoof, MD, Rosemary Pauley-Hunter, NP-C, and Mark Pimentel, MD, FRCP(C), who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Singh VV, Toskes PP. Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment. Curr Treat Options Gastroenterol 2004; 7:19.</a></li><li><a class="nounderline abstract_t">Quigley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24:943.</a></li><li><a class="nounderline abstract_t">Shah SC, Day LW, Somsouk M, Sewell JL. Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2013; 38:925.</a></li><li><a class="nounderline abstract_t">Attar A, Flourié B, Rambaud JC, et al. Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial. Gastroenterology 1999; 117:794.</a></li><li><a class="nounderline abstract_t">Tahan S, Melli LC, Mello CS, et al. Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum. J Pediatr Gastroenterol Nutr 2013; 57:316.</a></li><li><a class="nounderline abstract_t">Bouhnik Y, Alain S, Attar A, et al. Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome. Am J Gastroenterol 1999; 94:1327.</a></li><li><a class="nounderline abstract_t">Malik BA, Xie YY, Wine E, Huynh HQ. Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure. Can J Gastroenterol 2011; 25:41.</a></li><li><a class="nounderline abstract_t">Scarpellini E, Giorgio V, Gabrielli M, et al. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. Eur Rev Med Pharmacol Sci 2013; 17:1314.</a></li><li><a class="nounderline abstract_t">Pimentel M, Chang C, Chua KS, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci 2014; 59:1278.</a></li><li><a class="nounderline abstract_t">Pimentel M, Saad RJ, Long MD, Rao SSC. ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. Am J Gastroenterol 2020; 115:165.</a></li><li><a class="nounderline abstract_t">Vanderhoof JA, Young RJ, Murray N, Kaufman SS. Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome. J Pediatr Gastroenterol Nutr 1998; 27:155.</a></li><li><a class="nounderline abstract_t">Lauritano EC, Gabrielli M, Scarpellini E, et al. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. Am J Gastroenterol 2008; 103:2031.</a></li><li><a class="nounderline abstract_t">Lembo A, Pimentel M, Rao SS, et al. Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome. Gastroenterology 2016; 151:1113.</a></li><li><a class="nounderline abstract_t">Pimentel M, Constantino T, Kong Y, et al. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 2004; 49:73.</a></li><li><a class="nounderline abstract_t">Stotzer PO, Blomberg L, Conway PL, et al. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD. Scand J Infect Dis 1996; 28:615.</a></li><li><a class="nounderline abstract_t">Hegar B, Hutapea EI, Advani N, Vandenplas Y. A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole. J Pediatr (Rio J) 2013; 89:381.</a></li><li><a class="nounderline abstract_t">Gaon D, Garmendia C, Murrielo NO, et al. Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea. Medicina (B Aires) 2002; 62:159.</a></li><li><a class="nounderline abstract_t">Zhong C, Qu C, Wang B, et al. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence. J Clin Gastroenterol 2017; 51:300.</a></li><li><a class="nounderline abstract_t">Gottlieb K, Wacher V, Sliman J, Pimentel M. Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders. Aliment Pharmacol Ther 2016; 43:197.</a></li></ol></div><div id="topicVersionRevision">Topic 4778 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14723835" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Small Bowel Bacterial Overgrowth: Presentation, Diagnosis, and Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20937459" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Small intestinal bacterial overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24004101" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10500060" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Antibiotic efficacy in small intestinal bacterial overgrowth-related chronic diarrhea: a crossover, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974062" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effectiveness of trimethoprim-sulfamethoxazole and metronidazole in the treatment of small intestinal bacterial overgrowth in children living in a slum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235214" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Bacterial populations contaminating the upper gut in patients with small intestinal bacterial overgrowth syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258668" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Diagnosis and pharmacological management of small intestinal bacterial overgrowth in children with intestinal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23740443" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24788320" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Antibiotic treatment of constipation-predominant irritable bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32023228" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9702645" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Treatment strategies for small bowel bacterial overgrowth in short bowel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18802998" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Small intestinal bacterial overgrowth recurrence after antibiotic therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27528177" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14992438" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A 14-day elemental diet is highly effective in normalizing the lactulose breath test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9060066" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23796359" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : A double-blind placebo-controlled randomized trial on probiotics in small bowel bacterial overgrowth in children treated with omeprazole.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12038039" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Effect of Lactobacillus strains (L. casei and L. Acidophillus Strains cerela) on bacterial overgrowth-related chronic diarrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28267052" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth: A Meta-Analysis and Systematic Review of Current Evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26559904" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
